Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors

被引:7
|
作者
Gueiderikh, Anna [1 ]
Sarrade, Thomas [2 ]
Kirova, Youlia [3 ,4 ]
De La Lande, Brigitte [5 ]
De Vathaire, Florent [6 ,7 ,8 ]
Auzac, Guillaume [1 ]
Martin, Anne Laure [9 ]
Everhard, Sibille [9 ]
Meillan, Nicolas [7 ,10 ,11 ]
Bourgier, Celine [12 ,13 ,14 ]
Benyoucef, Ahmed [15 ]
Lacornerie, Thomas [16 ]
Pasquier, David [16 ,17 ,18 ]
Racadot, Severine [19 ]
Moignier, Alexandra [20 ]
Paris, Francois [20 ,21 ]
Andre, Fabrice [22 ,23 ]
Deutsch, Eric [1 ,10 ]
Duchemann, Boris [24 ]
Allodji, Rodrigue Setcheou [6 ,7 ,8 ]
Rivera, Sofia [1 ,10 ]
机构
[1] Gustave Roussy, Dept Radiat Therapy, Villejuif, France
[2] Tenon Hosp, Radiotherapy Dept, Paris, France
[3] Inst Curie, Dept Radiat Oncol, Paris, France
[4] Univ Versailles, St Quentin en Yvelines, France
[5] Inst Curie, Dept Radiat Oncol, St Cloud, France
[6] Gustave Roussy, Comprehens Canc Res Ctr, Villejuif, France
[7] Inst Natl Sante & Rech Med INSERM, Ctr Res Epidemiol & Populat Hlth, U1018, Villejuif, France
[8] Paris Saclay Univ, Unite Mixte Rech UMR 1018, Villejuif, France
[9] UNICANCER, Data Dept, Le Kremlin Bicetre, France
[10] Paris Saclay Univ, Inst Natl Sante & Rech Med INSERM 1030, Gustave Roussy, Villejuif, France
[11] CH Victor Dupouy, Radiat Therapy Dept, Argenteuil, France
[12] Montpellier Univ, Montpellier, France
[13] Inst Natl Sante & Rech Med INSERM, Inst Rech Cancerol Montpellier IRCM, U1194, Montpellier, France
[14] Inst Reg Canc Montpellier ICM, Federat Univ Oncol Radiotherapie Occitanie Medite, Montpellier, France
[15] Henri Becquerel Ctr, Radiat Therapy Dept, Rouen, France
[16] Ctr Oscar Lambret, Acad Dept Radiat Oncol, 3 Rue Combemale, Lille, France
[17] Univ Lille, Lille, France
[18] Ctr Natl Rech Sci CNRS, Cent Lille, Unite Mixte Rech UMR 9189, Ctr Rech Informat Signal & Automat Lille CRIStAL, Lille, France
[19] Ctr Leon Berard, Radiotherapy Dept, Lyon, France
[20] Inst Cancerol Ouest, Radiotherapy Dept, Nantes, France
[21] Nantes Univ, Inst Natl Sante & Rech Med INSERM, Ctr Natl Rech Sci CNRS, Nantes Angers Canc & Immunol Res Ctr CRCI2NA, Nantes, France
[22] Gustave Roussy, Med Oncol Dept, Villejuif, France
[23] Paris Saclay Univ, Inst Natl Sante & Rech Med INSERM, Gustave Roussy, U981, Villejuif, France
[24] Avicenne Hosp, Thorac Oncol, Bobigny, France
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
radio-induced lung injury; lug fibrosis; breast cancer; radiation therapy; CANTO cohort; RILI; dosimetric analyses; DOSE-VOLUME; FOLLOW-UP; RADIOTHERAPY; IRRADIATION; PNEUMONITIS; TOXICITY; FIBROSIS; TRIAL;
D O I
10.3389/fonc.2023.1199043
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeRadiation-induced lung injury (RILI) is strongly associated with various clinical conditions and dosimetric parameters. Former studies have led to reducing radiotherapy (RT) doses to the lung and have favored the discontinuation of tamoxifen during RT. However, the monocentric design and variability of dosimetric parameters chosen have limited further improvement. The aim of our study was to assess the incidence of RILI in current practice and to determine clinical and dosimetric risk factors associated with RILI occurrence. Material and methodsData from 3 out of the 10 top recruiting centers in CANTO-RT, a subset of the CANTO prospective longitudinal cohort (NCT01993498), were retrospectively analyzed for RILI occurrence. This cohort, which recruited invasive cT0-3 cN0-3 M0 breast cancer patients from 2012 to 2018, prospectively recorded the occurrence of adverse events by questionnaires and medical visits at the end of, and up to 60 months after treatment. RILI adverse events were defined in all patients by the association of clinical symptoms and compatible medical imaging. ResultsRILI was found in 38/1565 (2.4%) patients. Grade II RILI represented 15/38 events (39%) and grade III or IV 2/38 events (6%). There were no grade V events. The most frequently used technique for treatment was 3D conformational RT (96%). In univariable analyses, we confirmed the association of RILI occurrence with pulmonary medical history, absence of cardiovascular disease medical history, high pT and pN, chemotherapy use, nodal RT. All dosimetric parameters were highly correlated and had close predictive value. In the multivariable analysis adjusted for chemotherapy use and nodal involvement, pulmonary medical history (OR=3.05, p<0.01) and high V30 Gy (OR=1.06, p=0.04) remained statistically significant risk factors for RILI occurrence. V30 Gy >15% was significantly associated with RILI occurrence in a multivariable analysis (OR=3.07, p=0.03). ConclusionOur study confirms the pulmonary safety of breast 3D RT in CANTO-RT. Further analyses with modern radiation therapy techniques such as IMRT are needed. Our results argue in favor of a dose constraint to the ipsilateral lung using V30 Gy not exceeding 15%, especially in patients presenting pulmonary medical history. Pulmonary disease records should be taken into account for RT planning.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Radio-induced lung injury: clinical and dosimetric risk factors in a subset of the CANTO RT cohort
    Gueiderikh, A.
    Sarrade, T.
    Kirova, Y.
    De La Lande, B.
    De Vathaire, F.
    Auzac, G.
    Martin, A. L.
    Everhard, S.
    Duchemann, B.
    Allodji, R.
    Rivera, S.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S635 - S636
  • [2] Analysis of Clinical and Dosimetric Factors Influencing Radiation-Induced Lung Injury in Patients with Lung Cancer
    Han Shuiyun
    Gu, Feiying
    Lin, Gang
    Sun, Xiaojiang
    Wang, Yuezhen
    Wang, Zhun
    Lin, Qingren
    Weng, Denghu
    Xu, Yaping
    Mao, Weimin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S687 - S687
  • [3] Analysis of Clinical and Dosimetric Factors Influencing Radiation-Induced Lung Injury in Patients with Lung Cancer
    Han, Shuiyun
    Gu, Feiying
    Lin, Gang
    Sun, Xiaojiang
    Wang, Yuezhen
    Wang, Zhun
    Lin, Qingren
    Weng, Denghu
    Xu, Yaping
    Mao, Weimin
    JOURNAL OF CANCER, 2015, 6 (11): : 1172 - 1178
  • [4] Clinical and Dosimetric Risk Factors of Severe Radiation-induced Pulmonary Fibrosis in Lung Cancer
    Zhang, Z.
    Li, B.
    Xu, J.
    Yin, Y.
    Huang, Y.
    Li, H.
    Sun, H.
    Wang, Z.
    Yang, F.
    Zhu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S471 - S471
  • [5] Clinical and Dosimetric Risk Factors Associated With Radiation-Induced Lung Toxicities After Multiple Courses of Lung Stereotactic Body Radiation Therapy
    Li, Xingzhe
    Yorke, Ellen
    Jackson, Andrew
    Yue, Yujuan
    Simone, Charles B.
    Apte, Aditya P.
    Rimner, Andreas
    Gomez, Daniel R.
    Shaverdian, Narek
    Gelblum, Daphna Y.
    Wu, Abraham J.
    Shepherd, Annemarie F.
    ADVANCES IN RADIATION ONCOLOGY, 2024, 9 (01)
  • [6] Clinical and dosimetric factors of radiation-induced esophageal injury: Radiation-induced esophageal toxicity
    Qiao, Wen-Bo
    Zhao, Yan-Hui
    Zhao, Yan-Bin
    Wang, Rui-Zhi
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (17) : 2626 - 2629
  • [8] Imaging features of radiation-induced lung disease and its relationship with clinical and dosimetric factors in breast cancer patients
    Yilmaz, Ugur
    Koylu, Murat
    Savas, Recep
    Alanyali, Senem
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) : S409 - S416
  • [9] Clinical and dosimetric risk factors of radiation-induced acute esophageal toxicity in non-small cell lung cancer
    Zhang, Z. C.
    Li, B. S.
    Xu, J.
    Yin, Y.
    Lu, J.
    Li, H. S.
    Sun, H. F.
    Wang, Z. T.
    Liu, J.
    Liu, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S461 - S461
  • [10] Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: Clinical, dosimetric, and associated-treatment risk factors
    Leprieur, Etienne Giroux
    Fernandez, Diego
    Chatellier, Gilles
    Klotz, Sylvain
    Giraud, Philippe
    Durdux, Catherine
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (03) : 447 - 451